MA30723B1 - Benzoxazoles et oxazolopyridines utiles en tant qu'inhibiteurs des janus kinases. - Google Patents

Benzoxazoles et oxazolopyridines utiles en tant qu'inhibiteurs des janus kinases.

Info

Publication number
MA30723B1
MA30723B1 MA31738A MA31738A MA30723B1 MA 30723 B1 MA30723 B1 MA 30723B1 MA 31738 A MA31738 A MA 31738A MA 31738 A MA31738 A MA 31738A MA 30723 B1 MA30723 B1 MA 30723B1
Authority
MA
Morocco
Prior art keywords
disease
treatment
compounds
formula
oxazolopyridines
Prior art date
Application number
MA31738A
Other languages
English (en)
Inventor
Marc Gerspacher
Pascal Furet
Eric Vangrevelinghe
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37717673&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA30723(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA30723B1 publication Critical patent/MA30723B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'INVENTION CONCERNE DES COMPOSÉS 2,7-DISUBSTITUÉS BENZOXAZOLE ET 2,4-DISUBSTITUÉS OXAZOLO[5,4- C]PYRIDINE SELON LA FORMULE I ÉNONCÉE CI-DESSOUS, AINSI QUE LEURS SELS, LEURS PROCÉDÉS DE PRÉPARATION, LEUR MISE EN PRATIQUE DANS UN PROCÉDÉ DESTINÉ AU TRAITEMENT DU CORPS HUMAIN OU ANIMAL, L'UTILISATION DE CES COMPOSÉS DANS LE TRAITEMENT (Y COMPRIS LA PROPHYLAXIE) DU CORPS ANIMAL ET, PLUS PARTICULIÈREMENT, DU CORPS HUMAIN (PARTICULIÈREMENT EN RAPPORT AVEC UNE MALADIE PROLIFÉRANTE), LEUR UTILISATION, SEULS OU EN COMBINAISON AVEC UN OU PLUSIEURS COMPOSÉS PHARMACEUTIQUEMENT ACTIFS, POUR LE TRAITEMENT, EN PARTICULIER, D'UNE MALADIE INDUITE PAR LA PROTÉINE-TYROSINE KINASE (TELLE QU'UNE MALADIE TUMORALE) OU LA FABRICATION D'UNE PRÉPARATION PHARMACEUTIQUE DESTINÉE À ÊTRE UTILISÉE DANS LE TRAITEMENT D'UNE TELLE MALADIE, UN PROCÉDÉ DESTINÉ AU TRAITEMENT D'UNE TELLE MALADIE ET UNE PRÉPARATION PHARMACEUTIQUE DESTINÉE AU TRAITEMENT D'UNE MALADIE TELLE QUE MENTIONNÉE. LES COMPOSÉS SONT DÉCRITS PAR LA FORMULE I, LES SYMBOLES DE CETTE FORMULE ÉTANT TELS QUE DÉFINIS DANS LA DESCRIPTION. LES COMPOSÉS INHIBENT, PAR EXEMPLE, JAK2 ET JAK3.
MA31738A 2006-09-15 2009-03-30 Benzoxazoles et oxazolopyridines utiles en tant qu'inhibiteurs des janus kinases. MA30723B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06120733A EP1900729A1 (fr) 2006-09-15 2006-09-15 Benzoxazoles et oxazolopyridines et leur utilisation comme inhibiteurs de Janus kinases

Publications (1)

Publication Number Publication Date
MA30723B1 true MA30723B1 (fr) 2009-09-01

Family

ID=37717673

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31738A MA30723B1 (fr) 2006-09-15 2009-03-30 Benzoxazoles et oxazolopyridines utiles en tant qu'inhibiteurs des janus kinases.

Country Status (30)

Country Link
US (1) US8629168B2 (fr)
EP (2) EP1900729A1 (fr)
JP (1) JP5325105B2 (fr)
KR (1) KR20090064389A (fr)
CN (1) CN101516860B (fr)
AR (1) AR062786A1 (fr)
AT (1) ATE532774T1 (fr)
AU (1) AU2007296916B2 (fr)
BR (1) BRPI0716841A2 (fr)
CA (1) CA2660987A1 (fr)
CL (1) CL2007002669A1 (fr)
CO (1) CO6150142A2 (fr)
CR (1) CR10639A (fr)
EA (1) EA200900388A1 (fr)
ES (1) ES2377148T3 (fr)
GT (1) GT200900056A (fr)
IL (1) IL196860A0 (fr)
MA (1) MA30723B1 (fr)
MX (1) MX2009002812A (fr)
NO (1) NO20091469L (fr)
PA (1) PA8748101A1 (fr)
PE (1) PE20080842A1 (fr)
PL (1) PL2066647T3 (fr)
PT (1) PT2066647E (fr)
SM (1) SMP200900023B (fr)
TN (1) TN2009000070A1 (fr)
TW (1) TW200819444A (fr)
UY (1) UY30587A1 (fr)
WO (1) WO2008031594A1 (fr)
ZA (1) ZA200900477B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2467670B (en) 2007-10-04 2012-08-01 Intellikine Inc Chemical entities and therapeutic uses thereof
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
NZ590258A (en) 2008-07-08 2013-10-25 Intellikine Llc Kinase inhibitors and methods of use
AU2009270511B2 (en) * 2008-07-15 2013-07-18 Sanofi Oxazolopyrimidines as Edg-1 receptor agonists
AR073010A1 (es) * 2008-08-12 2010-10-06 Takeda Pharmaceutical Compuesto amida con actividad agonista del gpr52
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
EP2380877A4 (fr) 2008-11-28 2012-06-27 Kowa Co Dérivé de pyridine-3-carboxyamide
EP2518054A1 (fr) 2009-12-24 2012-10-31 Takeda Pharmaceutical Company Limited Composé amide
AR079980A1 (es) * 2010-01-13 2012-03-07 Sanofi Aventis Derivados de oxazolopirimidina sustituida en 2,5,7
TWI592411B (zh) 2011-02-23 2017-07-21 英特爾立秦有限責任公司 激酶抑制劑之組合及其用途
US8580816B2 (en) * 2011-07-07 2013-11-12 Sanofi Carboxylic acid derivatives having an oxazolo[5,4-b]pyridine ring
US8907093B2 (en) * 2011-07-07 2014-12-09 Sanofi Carboxylic acid derivatives having an oxazolo[4,5-c]pyridine ring
CN103102359B (zh) * 2011-11-15 2016-11-09 江苏先声药业有限公司 嘧啶类化合物及其应用
WO2013082476A1 (fr) 2011-11-30 2013-06-06 Emory University Inhibiteurs de jak antiviraux utiles dans le traitement ou la prévention d'infections rétrovirales et autres infections virales
WO2014075318A1 (fr) * 2012-11-19 2014-05-22 江苏先声药业有限公司 Composés de pyrimidine et utilisation associée
US9724354B2 (en) 2013-03-22 2017-08-08 Millennium Pharmaceuticals, Inc. Combination of catalytic mTORC1/2 inhibitors and selective inhibitors of Aurora A kinase
CN103664759A (zh) * 2013-12-06 2014-03-26 常熟市联创化学有限公司 一种3-羟基-2-硝基吡啶的制备方法
US9394237B2 (en) 2014-02-03 2016-07-19 Quadriga Biosciences, Inc. β-substituted β-amino acids and analogs as chemotherapeutic agents
CN106132406B (zh) 2014-02-03 2020-03-27 夸德里加生物科学公司 作为化疗剂的β-取代的γ-氨基酸和类似物
WO2016047678A1 (fr) * 2014-09-25 2016-03-31 武田薬品工業株式会社 Composé hétérocyclique
EP3331851A1 (fr) 2015-08-03 2018-06-13 Quadriga Biosciences, Inc. Acides bêta-aminés substitués en bêta et analogues à utiliser en tant qu'agents de chimiothérapie et leurs utilisations
TW202307005A (zh) 2021-05-28 2023-02-16 美商邊際分析公司 以核醣體蛋白質S6激酶α-1 (RSK1)及核醣體蛋白質S6激酶α-3 (RSK2)之調節劑治療神經病症之方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1382339E (pt) * 1999-12-10 2008-02-06 Pfizer Prod Inc Composições que contêm derivados de pirrolo[2,3-d]- pirimidina
SE0301373D0 (sv) 2003-05-09 2003-05-09 Astrazeneca Ab Novel compounds
DE10344223A1 (de) * 2003-09-24 2005-04-21 Merck Patent Gmbh 1,3-Benzoxazolylderivate als Kinase-Inhibitoren
GB0402140D0 (en) * 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
EP1674467A1 (fr) * 2004-12-22 2006-06-28 4Sc Ag Derives benzazoles 2,5- et 2,6-disubstitues utiles comme des inhibiteurs de la proteine kinase
JP4855468B2 (ja) * 2005-09-02 2012-01-18 エフ．ホフマン−ラ ロシュ アーゲー ベンゾオキサゾール、オキサゾロピリジン、ベンゾチアゾール及びチアゾロピリジン誘導体
CN101506177A (zh) * 2006-07-21 2009-08-12 诺瓦提斯公司 作为jak激酶抑制剂的2,4-二(芳基氨基)-嘧啶-5-酰胺化合物

Also Published As

Publication number Publication date
CO6150142A2 (es) 2010-04-20
PA8748101A1 (es) 2009-08-26
CR10639A (es) 2009-07-03
NO20091469L (no) 2009-04-15
TW200819444A (en) 2008-05-01
KR20090064389A (ko) 2009-06-18
PL2066647T3 (pl) 2012-04-30
TN2009000070A1 (en) 2010-08-19
PE20080842A1 (es) 2008-08-11
ATE532774T1 (de) 2011-11-15
ZA200900477B (en) 2010-01-27
EA200900388A1 (ru) 2009-08-28
UY30587A1 (es) 2008-05-02
EP1900729A1 (fr) 2008-03-19
US20100009978A1 (en) 2010-01-14
EP2066647A1 (fr) 2009-06-10
AR062786A1 (es) 2008-12-03
ES2377148T3 (es) 2012-03-22
US8629168B2 (en) 2014-01-14
WO2008031594A1 (fr) 2008-03-20
CN101516860B (zh) 2012-06-27
SMP200900023B (it) 2009-07-14
GT200900056A (es) 2011-11-08
MX2009002812A (es) 2009-03-31
BRPI0716841A2 (pt) 2013-10-01
EP2066647B1 (fr) 2011-11-09
CL2007002669A1 (es) 2008-05-09
IL196860A0 (en) 2009-11-18
CN101516860A (zh) 2009-08-26
JP2010503629A (ja) 2010-02-04
PT2066647E (pt) 2012-01-17
CA2660987A1 (fr) 2008-03-20
SMAP200900023A (it) 2009-05-11
AU2007296916B2 (en) 2011-10-06
JP5325105B2 (ja) 2013-10-23
AU2007296916A1 (en) 2008-03-20

Similar Documents

Publication Publication Date Title
MA30723B1 (fr) Benzoxazoles et oxazolopyridines utiles en tant qu'inhibiteurs des janus kinases.
MA33502B1 (fr) Composés pyrazolopyrimidine inhibiteurs des jak et procédés
TNSN05298A1 (fr) Derives de pyrazolo-quinazoline, procede pour leur preparation et leur utilisation comme inhibiteurs de kinases
MA47399A (fr) Dérivés de 7-phényléthylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one en tant qu'inhibiteurs de la forme mutée des protéines idh1 et idh2
MA28064A1 (fr) Dérivés de pyrrolo [3,4-c] pyrazole actifs comme inhibiteurs de kinases
MA30089B1 (fr) (arylsulfonyl)-pyrasolopiperidines
TNSN05176A1 (fr) Derives de diazepino-indole servant d'inhibiteurs de kinases
TNSN08270A1 (fr) Dérivés pyrimidiques destinés à traiter une croissance cellulaire anormale
MA47079A (fr) Composés amino-triazolopyidines et leur utilisation pour traiter le cancer
MA28429B1 (fr) Dérivés de 1H-thiéno [2,3-c] pyrazole utiles comme inhibiteurs de kinases
MA30333B1 (fr) Aminotetrahydropyranes utiles en tant qu'inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete.
MA33636B1 (fr) Dérivés aminopropioniques substitués comme inhibiteurs de néprilysine
MA30073B1 (fr) Derives de piperidine 3,5-substitues en tant qu'inhibiteurs de renine
MA27774A1 (fr) Inhibiteurs de phosphatidylinositol 3-kinase
MA29378B1 (fr) Composition pharmaceutique comprenant une diphenyluree substituee par un omega-carboxyaryle pour le traitement du cancer
TN2009000544A1 (fr) Derives de benzimidazole
MA29713B1 (fr) Derives de tetrahydroindolone et de tetrahydroindazolone
TN2009000138A1 (fr) Biaryl-ether-urees
MA30351B1 (fr) Composes de tetrahydropyridothienopyrimidine et leurs procedes d'utilisation
MA30411B1 (fr) Derives de triazolopyrazine utiles comme agent anticancereux
MA33239B1 (fr) 3h-imidazo [4,5-c] pyridine-6-carboxamides en tant qu'anti-inflammatoires
MA29692B1 (fr) Derives de la xanthine en tant qu'agonistes selectifs du hm74a
TN2009000428A1 (fr) Derives de sulfonylamides destines au traitement d'une croissance cellulaire anormale
MA30532B1 (fr) Sulfonamides tricycliques condenses inhibiteurs de gamma-secretase
MA32306B1 (fr) Derives de quinoleines et de quinoxalines en tant qu'inhibiteurs de proteine tyrosine kinases